Skip to main content
. 2011 Jul 13;13(11):1213–1224. doi: 10.1093/neuonc/nor067

Fig. 2.

Fig. 2.

Effect of lanatoside C and/or tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) on glioblastoma multiforme (GBM) tumors in vivo. U87 glioma cells expressing Gluc were implanted subcutaneously in nude mice. One week later, mice were intraperitoneally injected once per day over 10 days with either DMSO vehicle (control), TRAIL (250 µg/kg body weight), lanatoside C (6 mg/kg body weight), or similar doses of both lanatoside C and TRAIL. (A) In vivo Gluc bioluminescence imaging was performed once per week after intravenous injection of coelenterazine, and photon counts were acquired using a CCD camera. (B) Before and at different time points (twice per week) after treatment, 5 µL of blood was drawn and assayed for Gluc activity. Shown is a representative mouse from each group (A) and the  mean ± standard deviation for Gluc blood assay from each group (B; n = 10).